Page last updated: 2024-12-08

aezs 124

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2-diethylaminoethyl)-N-(2-hydroxy-2-phenylethyl)-2,5-dichloroaniline: inhibitor of platelet aggregation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	183761
CHEMBL ID	3276232
SCHEMBL ID	11748369
MeSH ID	M0540742

Synonyms (13)

Synonym
rmi 6792
aezs124
benzenemethanol, alpha-(((2,5-dichlorophenyl)(2-(diethylamino)ethyl)amino)methyl)-
33189-65-0
aezs-124
alpha-(((2,5-dichlorophenyl)(2-(diethylamino)ethyl)amino)methyl)benzenemethanol
an 162
aezs 124
n-(2-diethylaminoethyl)-n-(2-hydroxy-2-phenylethyl)-2,5-dichloroaniline
CHEMBL3276232
SCHEMBL11748369
2-{(2,5-dichlorophenyl)[2-(diethylamino)ethyl]amino}-1-phenylethan-1-ol
DTXSID30954805

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay ID	Title	Year	Journal	Article
AID1145242	Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 30 ug/ml after 20 mins by aggregometric analysis relative to control	1976	Journal of medicinal chemistry, Apr, Volume: 19, Issue:4	Substituted alpah-methylbenzyl and tricyclic arylalkyl lactamimides as inhibitors of blood platelet aggregation.
AID1145244	Antiplatelet activity in human platelet rich plasma assessed as inhibition of platelet factor-3 release at 300 ug/ml after 20 mins relative to control	1976	Journal of medicinal chemistry, Apr, Volume: 19, Issue:4	Substituted alpah-methylbenzyl and tricyclic arylalkyl lactamimides as inhibitors of blood platelet aggregation.
AID1145241	Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 100 ug/ml after 20 mins by aggregometric analysis relative to control	1976	Journal of medicinal chemistry, Apr, Volume: 19, Issue:4	Substituted alpah-methylbenzyl and tricyclic arylalkyl lactamimides as inhibitors of blood platelet aggregation.
AID1145245	Antiplatelet activity in human platelet rich plasma assessed as inhibition of platelet factor-3 release at 100 ug/ml after 20 mins relative to control	1976	Journal of medicinal chemistry, Apr, Volume: 19, Issue:4	Substituted alpah-methylbenzyl and tricyclic arylalkyl lactamimides as inhibitors of blood platelet aggregation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (20.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (40.00)	29.6817
2010's	4 (40.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.70 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.09 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.70)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
procaine Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.	1.95	1	benzoate ester; substituted aniline; tertiary amino compound	central nervous system depressant; drug allergen; local anaesthetic; peripheral nervous system drug
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	1.95	1	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.73	3	pyrrole; secondary amine
phe-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2 RC 121: RN given refers to (D-Trp)-isomer	2.43	2
cetrorelix cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.	2.08	1	oligopeptide	antineoplastic agent; GnRH antagonist
sermorelin Sermorelin: The biologically active fragment of human growth hormone-releasing factor, consisting of GHRH(1-29)-amide. This N-terminal sequence is identical in several mammalian species, such as human, pig, and cattle. It is used to diagnose or treat patients with GROWTH HORMONE deficiency.. sermorelin : A 29 amino acid polypeptide that is used to treat growth problems (usually in children) due to growth hormone deficiency. It is the biologically active fragment of human growth hormone-releasing factor (GHRH).	2.08	1

Condition	Relationship Strength	Studies
Breast Cancer [description not available]	2.47	2
Breast Neoplasms Tumors or cancer of the human BREAST.	2.47	2
Carcinoma, Non-Small Cell Lung [description not available]	2.05	1
Cancer of Lung [description not available]	2.05	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.05	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.05	1
Adrenal Cancer [description not available]	2.47	2
Cancer of Colon [description not available]	2.05	1
Experimental Leukemia [description not available]	2.05	1
Colorectal Cancer [description not available]	2.05	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.05	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.05	1
Astrocytoma, Grade IV [description not available]	2.05	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.05	1
Pheochromocytoma, Extra-Adrenal [description not available]	2.08	1
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	2.08	1
HbS Disease [description not available]	1.95	1
Anemia, Sickle Cell A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.	1.95	1

chemdatabank.com